HK1077230A1 - Medicinal composition hmg-coa reductase inhibitor - Google Patents
Medicinal composition hmg-coa reductase inhibitorInfo
- Publication number
- HK1077230A1 HK1077230A1 HK05111984A HK05111984A HK1077230A1 HK 1077230 A1 HK1077230 A1 HK 1077230A1 HK 05111984 A HK05111984 A HK 05111984A HK 05111984 A HK05111984 A HK 05111984A HK 1077230 A1 HK1077230 A1 HK 1077230A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hmg
- coa reductase
- reductase inhibitor
- medicinal composition
- medicinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002225979 | 2002-08-02 | ||
JP2002260719 | 2002-09-06 | ||
PCT/JP2003/009835 WO2004012740A1 (en) | 2002-08-02 | 2003-08-01 | MEDICINAL COMPOSITION CONTAINING HMG-CoA REDUCTASE INHIBITOR |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1077230A1 true HK1077230A1 (en) | 2006-02-10 |
Family
ID=31497621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK05111984A HK1077230A1 (en) | 2002-08-02 | 2005-12-23 | Medicinal composition hmg-coa reductase inhibitor |
Country Status (6)
Country | Link |
---|---|
JP (1) | JP2010150288A (en) |
AU (1) | AU2003252358A1 (en) |
CA (1) | CA2494801A1 (en) |
HK (1) | HK1077230A1 (en) |
TW (1) | TW200409635A (en) |
WO (1) | WO2004012740A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102294439B1 (en) * | 2018-11-02 | 2021-08-27 | 경북대학교 산학협력단 | Compositions for preventing or treating macular degeneration |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54135740A (en) * | 1978-04-13 | 1979-10-22 | Otsuka Nobuhiro | Method of dissolving oryznol to greases or their products |
JP2000508659A (en) * | 1996-04-17 | 2000-07-11 | メルク エンド カンパニー インコーポレーテッド | Combination therapy to reduce cardiovascular disease-related risks |
NZ520176A (en) * | 1997-07-31 | 2005-02-25 | Kos Life Sciences Inc | Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night |
JP3597437B2 (en) * | 2000-02-10 | 2004-12-08 | 日清オイリオグループ株式会社 | Edible fats and oils with blood lipid improving function |
AU2001295991A1 (en) * | 2000-10-23 | 2002-05-06 | Sankyo Company Limited | Compositions for improving lipids in blood |
-
2003
- 2003-08-01 AU AU2003252358A patent/AU2003252358A1/en not_active Abandoned
- 2003-08-01 TW TW092121123A patent/TW200409635A/en unknown
- 2003-08-01 CA CA002494801A patent/CA2494801A1/en not_active Abandoned
- 2003-08-01 WO PCT/JP2003/009835 patent/WO2004012740A1/en not_active Application Discontinuation
-
2005
- 2005-12-23 HK HK05111984A patent/HK1077230A1/en not_active IP Right Cessation
-
2010
- 2010-03-24 JP JP2010067405A patent/JP2010150288A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2010150288A (en) | 2010-07-08 |
WO2004012740A1 (en) | 2004-02-12 |
CA2494801A1 (en) | 2004-02-12 |
TW200409635A (en) | 2004-06-16 |
AU2003252358A1 (en) | 2004-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1223918T3 (en) | Pharmaceutical compositions comprising an HMG-CoA reductase inhibitor | |
IL166279A0 (en) | Composition comprising a cholesterol absorption inhibitor an HMG-COA reductase inhibitor and a stabilizing agent | |
PL373146A1 (en) | Pyridazinone-derivatives as pde4 inhibitors | |
DE60202452D1 (en) | PYRIDAZINONAL DOSE REDUCTASE INHIBITORS | |
AU2003255376A1 (en) | Piperidine-derivatives as pde4 inhibitors | |
AU2003259749A1 (en) | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | |
AU2003202263A1 (en) | Roh-kinase inhibitors | |
AU2003278088A1 (en) | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | |
AU2003291103A8 (en) | Pharmaceutical composition | |
HK1080734A1 (en) | Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor | |
EP1684754A4 (en) | Hmg-coa reductase inhibitors and method | |
IL163929A0 (en) | Combination comprising an hmg-coa reductase inhibitor and an insulin secretor enhancer or an insulinsensitizer | |
EP1425019A4 (en) | Pharmaceutical composition | |
AU2003250372A8 (en) | Pharmaceutical composition | |
AU2003250172A1 (en) | Compositions comprising hmg-coa reductase inhibitor | |
AU2003232848A1 (en) | Phenylaminopyrimidines and their use as rho-kinase inhibitors | |
AU2002310798A1 (en) | Pharmaceutical compositions comprising a hmg-coa reductase inhibitor | |
IL166331A0 (en) | 5-arylterazole compounds compositions thereof and uses therefor | |
AU2003277674A1 (en) | Novel parp inhibitors | |
PL374581A1 (en) | Diaminothiazoles and use thereof as cdk4 inhibitors | |
ZA200508204B (en) | Pharmaceutical composition of atorvastatin | |
EP1400571A3 (en) | Aerosol composition | |
AU2003215635A1 (en) | Thiazol-2-yl-imine compounds as pde-7 inhibitors | |
EP1871396A4 (en) | Stabilized pharmaceutical compositions comprising an hmg-coa reductase inhibitor | |
HK1081843A1 (en) | Pharmaceutical composition comprising reductase inhibitor hmg-coa and melatonin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20120801 |